Table 3.

The growth data of the hepatic remnant after SOAP and the short-term and long-term outcomes after the second-stage operation

Variable	Terminal FLRV (ml), % of the SLV	Growth rate (ml/day)	Time interval (days)	Growth range (%)	CCI	AFP* (ng/ml)	LOS* (days)	DFS (months)	OS (months), status
Patient 1	550, 53.5%	18.4	12	30.60	8.7	15.9	19	4	9.2, dead
Patient 2	456, 41.9%	20.6	8	46.20	8.7	18.1	9	> 40.2	40.2, alive without disease
Patient 3	531, 37.7%	16.5	13	51.70	43.3	4.7	12	7	13.8, dead
Patient 4	642, 49.0%	10.9	15	25.60	8.7	8.5	26	3.6	9.5, dead
Patient 5	715, 54.1%	25.8	17	41.60	8.7	9.9	13	6.2	20.8, alive with disease
Patient 6	581, 43.8%	10.4	15	27.40	8.7	3.2	12	> 13.3	13.3, alive without disease
Patient 7	420, 37.8%	9	18	37.70	27.6	289.2	22	2.2	14.5, dead
Patient 8	516, 45.6%	10.9	13	34.00	8.7	14.8	14	6.5	13.5, alive with disease
Patient 9	498, 42.7%	10	16	39.10	8.7	19.3	18	> 10.5	10.5, alive without disease

FLRV the volume of the future liver remnant, terminal FLRV the FLRV before the second-stage operation, growth rate the kinetic growth rate of the FLRV, time interval the time interval between the two stages, SLV standard liver volume, growth range = (FLRV after operation—FLRV before operation)/FLRV before operation × 100%, DFS disease-free survival time, OS overall survival time, CCI the comprehensive complication index, AFP* the level of serum alpha-fetoprotein 2 months after the second-stage operation, LOS* the length of hospital stay after the second operation. The end of follow-up is December 1, 2018